Catastrophic Antiphospholipid Syndrome Market To Reach $8.99 Billion By 2030

Catastrophic Antiphospholipid Syndrome Market Growth & Trends

The global catastrophic antiphospholipid syndrome market size is anticipated to reach USD 8.99 billion by 2030 and is projected to grow at a CAGR of 10.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses various aspects related to the diagnosis, treatment, and management of this rare and life-threatening autoimmune disorder.

The rising demand for effective treatment options is critical in the catastrophic antiphospholipid syndrome (CAPS) market. Patients and healthcare providers are actively seeking innovative therapies that can address the unique challenges posed by CAPS, including its rapid progression and multi-organ involvement. The clinical trials are focused on developing targeted therapies that mitigate the severe thrombotic events associated with the syndrome.

The rising prevalence of autoimmune disorders is anticipated to drive the market growth. Autoimmune disorders involve an abnormal immune response where the body mistakenly attacks its tissues. APS, a type of autoimmune disease, can lead to complications, including digestive issues such as irritable bowel syndrome (IBS). According to Crohn’s and  Colitis Canada, over 322,600 Canadians were estimated to be living with inflammatory bowel disease (IBD) in 2023, which represents about 0.82% of the total population.

 Request a free sample copy or view report summary: Catastrophic Antiphospholipid Syndrome Market Report

Catastrophic Antiphospholipid Syndrome Market Report Highlights

• Based on treatment, the intravenous immunoglobulin (IVIG) segment led the market with the largest revenue share of 36.93% in 2023. The efficacy of IVIG is supported by various clinical instances where patients with refractory CAPS showed improvement after receiving this therapy, often in conjunction with other treatments such as anticoagulation and corticosteroids

• Based on end-use, the hospital segment led the market with the largest revenue share of 62.80% in 2023. The increasing prevalence of autoimmune diseases and the growing awareness of CAPS among healthcare providers fuel the demand for hospital-based care, as timely interventions can significantly improve patient outcomes and reduce mortality rates associated with this life-threatening condition

Catastrophic Antiphospholipid Syndrome Market Segmentation

Grand View Research has segmented global catastrophic antiphospholipid syndrome market report based on treatment, end-use, and region:

Catastrophic Antiphospholipid Syndrome Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Anticoagulants

• Immunosuppressive Therapy

• Plasma Exchange Therapy (Plasmapheresis)

• Intravenous Immunoglobulin (IVIG)

• Other Treatment

Catastrophic Antiphospholipid Syndrome End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Clinics

• Other

Catastrophic Antiphospholipid Syndrome Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Catastrophic Antiphospholipid Syndrome Market

• Pfizer

• Abbott

• Bristol-Myers Squibb Company

• Eli Lilly and Company

• Boehringer Ingelheim International GmbH

• Novartis AG

• Merck KGaA

• AbbVie Inc.

• F. Hoffmann-La Roche

• Johnson & Johnson Services, Inc.